# A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

Study · id `cardio:ct-nct07625215` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07625215](<https://clinicaltrials.gov/study/NCT07625215>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07625215

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 360 participants.

## Technical summary

Registry record NCT07625215. Randomized; double masking; primary purpose treatment. Start 2026-09-01 (actual); primary completion 2030-05-16 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 360 participants (planned count; ClinicalTrials.gov record NCT07625215, source copy `cardio:ctgov-nct07625215-2026-10-20`, retrieved 2026-10-26)
- Started: 2026-09-01 (actual) (ClinicalTrials.gov record NCT07625215, source copy `cardio:ctgov-nct07625215-2026-10-20`, retrieved 2026-10-26)
- Primary completion: 2030-05-16 (anticipated) (ClinicalTrials.gov record NCT07625215, source copy `cardio:ctgov-nct07625215-2026-10-20`, retrieved 2026-10-26)
- Completion: 2030-05-16 (anticipated) (ClinicalTrials.gov record NCT07625215, source copy `cardio:ctgov-nct07625215-2026-10-20`, retrieved 2026-10-26)
- Countries: United States; Belgium; Bulgaria; Germany; Hungary; Italy; Netherlands; Poland (ClinicalTrials.gov record NCT07625215, source copy `cardio:ctgov-nct07625215-2026-10-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07625215-2026-10-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
- Acronym: CARDIOVERT
- Condition: Atrial Fibrillation
- Intervention (Drug): BAY 3670549
- Intervention (Other): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: 6d03f18c0ba3b6fd3a1f3b1ed71912f57068494649c8b88986d0ab052b54e430
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
